IGC Pharma Reports IGC-M3’s In Vitro Efficacy Against Alzheimer’s – Targeting key Drivers of Disease Progression August 5, 2025 Read More »
IGC Pharma to Present Advanced AI Platforms for Alzheimer’s Disease at the AAIC 2025 July 23, 2025 Read More »
IGC Pharma’s Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards July 21, 2025 Read More »
IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer’s Risk and Accelerate Early Detection July 10, 2025 Read More »
IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights – A Year of Transformative Progress in Alzheimer’s Innovation June 30, 2025 Read More »
IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on June 30, 2025 June 27, 2025 Read More »
IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon June 23, 2025 Read More »
IGC Pharma’s Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer’s Market May 22, 2025 Read More »
IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting May 12, 2025 Read More »
